• Natural compound inducers of immunogenic cell death

• Diederich Marc

• Archives of Pharmacal Research   2019  Volume.42  No.7 629 ~ 645

• Phosphatidylserine receptor-targeting therapies for the treatment of cancer

• Park Mi-So

• Kang Keon-Wook

• Archives of Pharmacal Research   2019  Volume.42  No.7 617 ~ 628

• Evolution of chimeric antigen receptor (CAR) T cell therapy: current status and future perspectives

• Lee Young-Ho

• Kim Chan-Hyuk

• Archives of Pharmacal Research   2019  Volume.42  No.7 607 ~ 616

• Natural killer cells as a promising therapeutic target for cancer immunotherapy

• Kim Na-Young

• Lee Hyeon-Ho, Lee Hyo-Jung, Choi Woo-Seon, Lee Jin-Ju, Kim Hun-Sik

• Archives of Pharmacal Research   2019  Volume.42  No.7 591 ~ 606

• Transendothelial migration (TEM) of in vitro generated dendritic cell vaccine in cancer immunotherap...

• Ashraf Muhammad Umer

• Jeong Yi-Deul, Roh Seung-Eon, Bae Yong-Soo

• Archives of Pharmacal Research   2019  Volume.42  No.7 582 ~ 590

• Immunological and clinical implications of immune checkpoint blockade in human cancer

• Kim Hyung-Don

• Park Su-Hyung

• Archives of Pharmacal Research   2019  Volume.42  No.7 567 ~ 581

• Role of myeloid-derived suppressor cells in immune checkpoint inhibitor therapy in cancer

• Park Su-Myeong

• Youn Je-In

• Archives of Pharmacal Research   2019  Volume.42  No.7 560 ~ 566

• T helper 17 (Th17) cells and interleukin-17 (IL-17) in cancer

• Chang Seon-Hee

• Archives of Pharmacal Research   2019  Volume.42  No.7 549 ~ 559

• Roles of NKT cells in cancer immunotherapy

• Bae Eun-Ah

• Seo Hyung-Seok, Kim Il-Kyu, Jeon In-Su, Kang Chang-Yuil

• Archives of Pharmacal Research   2019  Volume.42  No.7 543 ~ 548